Clazol (Cilostazol) is commonly used to help with symptoms that create noticeable functional strain, particularly those associated with Intermittent Claudication and Peripheral Arterial Disease (PAD). This medication is considered relevant for use in conditions where patients experience these symptomatic manifestations.

The medication is relevant for easing symptoms that interfere with daily functioning, such as pain, cramping, or aching in the legs. Clazol is applied across domains where additional symptomatic support is needed, specifically in conditions presenting with systemic or localized discomfort and those associated with chronic circulatory compromise. The use of Clazol generally contributes to easing the overall symptom burden and may assist with maintaining functional stability during symptomatic periods.

This supportive therapy is relevant in clinical settings that involve acute or unstable symptom patterns, and it is commonly used to help with symptoms that create noticeable functional strain. This medication may be part of symptomatic management applied in scenarios where additional management of discomfort is required.

Quick Fact: Used for Functional Mobility Support

Quick Fact: Used for Functional Mobility Support – Clazol is commonly used to help manage symptoms that interfere with daily functioning, contributing to improved comfort during symptomatic periods and assists with maintaining functional stability.

Regulatory References

1. Cilostazol overview

Who Can and Cannot Use Clazol? (Cilostazol)

Clazol is restricted to use in adults who are non-eligible for specific contraindications detailed in official regulatory documentation. The safety and efficacy of Clazol in the pediatric population (children and adolescents) have not been established.

Absolute Contraindications (Must Not Use)

According to official regulatory labeling, Clazol is contraindicated and must not be used by patients with the following conditions:

• Heart failure of any severity.
• A known hypersensitivity to the active substance, Cilostazol.
• Any predisposition to bleeding, including active peptic ulceration or recent (within six months) hemorrhagic stroke.
• Severe renal impairment (creatinine clearance CrCl leq 25 mL/min).
• Moderate or severe hepatic impairment.
• Pregnancy or during breastfeeding (use is not recommended).
• Severe tachyarrhythmia, unstable angina pectoris, or myocardial infarction/coronary intervention in the last six months.
• Concomitant treatment with two or more additional antiplatelet or anticoagulant agents.

Use-Related Limitations

Use is allowed with caution in patients with mild hepatic disease or mild to moderate renal impairment. Furthermore, patients receiving strong inhibitors of CYP3A4 or CYP2C19 are required to receive a reduced dose of the medicine.

The interaction profile of Clazol (Cilostazol) is defined by pharmacokinetic and pharmacodynamic patterns documented in official regulatory sources.

Interaction Scope

Pharmacokinetic Interactions (CYP)

Concomitant use with strong or moderate inhibitors of CYP3A4 (such as ketoconazole or erythromycin) or CYP2C19 (such as omeprazole) results in a significant increase in the systemic exposure (Cmax and AUC) of Cilostazol and its active metabolites. This enzyme-mediated interaction necessitates a formal dose adjustment, as required by drug labels.

Pharmacodynamic Interactions and Restrictions

Cilostazol’s antiplatelet activity contributes to an increased risk of hemorrhage when combined with other antithrombotic agents. Consequently, official prescribing information formally contraindicates the co-administration of Cilostazol with two or more additional antiplatelet or anticoagulant medicines.

Timing-Based Interaction Rules

The drug's absorption is affected by intake timing. A high-fat meal increases absorption; therefore, administration must be separated from meals by at least thirty minutes before or two hours after eating.

Population-Specific Cautions

Due to the drug’s metabolic profile, Cilostazol is officially contraindicated in patients with severe hepatic impairment or severe renal impairment.

Clazol is a small molecule that initiates its function by inducing the stabilization of the A2 R receptor. This interaction fundamentally influences the balance of PTH- cAMP signaling. The downstream mechanism involves the allosteric inhibition of the N6 enzyme, a process that results in a measurable reduction of R1 protein phosphorylation. This specific intracellular cascade modulates bone remodeling kinetics. Clazol's action is specific to the intracellular enzyme N6, where it acts as a non-competitive inhibitor. This binding alters the enzyme's conformation, decreasing its catalytic rate toward R1. The resulting change in protein activity alters the cellular processes responsible for mineral homeostasis and turnover within the bone tissue matrix.

Clazol, which contains the active ingredient Cilostazol, is administered via the oral route as a single-ingredient tablet. The medication is available in strengths of 50 mg and 100 mg.

Standard Use Protocol

The standard dosage regimen is 100 mg taken twice daily. This standard pattern establishes the general frequency for the administration of the drug.

Timing and Administration

A key principle of Clazol usage relates to its specific administration timing relative to food intake. The tablets are taken on an empty stomach to maintain consistent systemic delivery. This procedural requirement dictates that each dose should be taken at least 30 minutes before or 2 hours after breakfast and the evening meal.

Duration and Assessment

The time course of therapy is defined: patients may require a treatment duration of up to 12 weeks (3 months) before the full beneficial effect of the medication can be accurately assessed. Following this assessment period, if no clinically relevant improvement in symptoms is observed, therapy should be discontinued.

Dosage Adjustment Principles

There are circumstances where the standard dose requires modification, specifically related to co-administered medications. For patients concurrently taking strong or moderate inhibitors of certain liver enzymes, the dose is reduced to 50 mg taken twice daily. For populations such as older adults or those with mild hepatic or renal impairment, no special dosage adjustment is considered necessary.

Research Evidence / Overview of Studies for Clazol

Evidence for Use in Intermittent Claudication

The primary research for Clazol (Cilostazol) was studied for its use in patients with symptoms of Intermittent Claudication (IC), the pain or cramping in the legs associated with Peripheral Arterial Disease (PAD). The evidence is primarily drawn from multiple short-term, randomized, placebo-controlled trials (RCTs). These trials contribute significantly to the body of evidence for exploring how symptoms change over a specific time period.

Research examined outcomes related to functional capacity and physical discomfort. Studies used standardized treadmill tests to measure pain-free walking distance and maximal walking distance. Findings describe patterns observed in the studies that were related to measurements of walking distances between the groups receiving the drug and the placebo groups. Long-term outcomes are not well characterized because the main RCTs had limited follow-up durations, typically less than one year.

Evidence for Use in Secondary Stroke Prevention

Clazol was evaluated in large-scale randomized trials applied in studies examining the risk of recurrent ischemic stroke in adults who had previously experienced a stroke or TIA. Research examined whether the drug was associated with differences in the rate of recurrent stroke. A key consideration is that the majority of the most extensive and definitive trials for this use have been conducted in Asian patient populations. This means that results apply only to the populations studied, and data for certain other groups remain insufficient to fully establish consistency.

Research Gaps and Remaining Uncertainties

The evidence base is largely structured around outcomes measured during the short-to-intermediate-term. Data remain limited on long-term outcomes beyond the defined study periods for both Intermittent Claudication and post-revascularization use. Furthermore, the large trials that defined the evidence base often excluded patients with severe or unstable cardiovascular conditions, meaning that study results reflect the specific conditions under which they were conducted. Studies contribute to understanding how findings observed in highly controlled clinical trial settings relate to various real-world patient populations.

Common questions about Clazol (FAQ)

Q: What should I do if I miss a dose of this medication?

Official instructions describe the standard procedure for a missed dose: if it is remembered soon after the scheduled time, the dose can be taken. However, if it is nearly time for the next dose, the missed dose is typically skipped, and the individual returns to the regular dosing schedule.

The regulatory labeling specifies that a double dose should not be taken to compensate for a missed dose.

Q: Are there any long-term side effects or health risks associated with taking this medication for several years?

Official product labeling, which includes data from clinical trials and post-marketing reports, provides information on adverse reactions observed across various body systems.

Regulatory documents include warnings about the potential for serious effects, such as a decrease in platelet or white blood cell counts (known as thrombocytopenia or leukopenia). The official labeling also carries a Black Box Warning regarding risks for individuals with existing heart failure, which represents a major safety consideration.

Q: Is this medication safe to use during pregnancy or while breastfeeding?

The medication is officially categorized as Pregnancy Category C, which indicates that there are no adequate and well-controlled studies in pregnant women. Animal studies, however, suggest a potential risk to the fetus.

Due to the potential for serious adverse reactions in a nursing infant, and evidence that the drug transfers into milk in animal models, the regulatory guidance states that a choice is typically made to discontinue either nursing or the drug.

Q: Are there any known interactions between this drug and common vitamins or herbal supplements?

Official regulatory information focuses on how the drug is processed by the body through specific liver enzymes, primarily CYP3A4 and CYP2C19. Strong or moderate inhibitors of these enzymes are known to increase the amount of Clazol in the body.

While specific vitamins or supplements are not always named in the labeling, if they are known to affect these same liver enzymes, the regulatory text outlines circumstances where a dosage adjustment is formally required.

Q: How long does the drug stay in my system (e.g., half-life and clearance)?

According to official pharmacokinetic data, Clazol and its active components are eliminated from the body relatively slowly. The time it takes for the concentration of the drug and its active metabolites to decrease by half (half-life) is approximately 11 to 13 hours.

Clazol is cleared from the system mainly by the liver, which converts it into metabolites that are subsequently excreted, primarily through the urine.

Q: Is this a controlled substance or scheduled drug?

Official government listings indicate that Clazol (Cilostazol) is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling system.

Q: Will I need to have regular blood tests or other monitoring while taking this medication?

Official warnings note a risk of blood cell abnormalities, including decreases in white blood cells (leukopenia) and platelets (thrombocytopenia). In rare cases, this may progress to a severe blood condition (agranulocytosis).

Official prescribing information describes the requirement that blood platelets and white blood cell counts be monitored periodically to check for these potential adverse reactions.

Q: Can this medication interact with oral birth control pills?

The drug's official label focuses on general enzyme pathways rather than naming every possible interacting medication, including specific oral contraceptives. Clazol is processed by liver enzymes like CYP3A4 and CYP2C19.

Since many other medications, including hormonal products, may also be processed by these enzymes, the potential for interactions is described through the general enzyme pathway information provided in the regulatory text.

Q: Is there a generic version of this drug available?

Yes, Clazol is the brand name for the active ingredient cilostazol. Cilostazol has been approved by regulatory bodies and is available as a generic drug product.

Q: Does this medication have a Black Box Warning?

Yes, Clazol carries a Boxed Warning in its official regulatory labeling, which represents the most serious type of caution required by the FDA.

This warning states that the drug is contraindicated (must not be used) in patients with heart failure of any severity. This is because the drug works similarly to other agents that have been associated with decreased survival in patients with heart failure.

Clazol should be stored in its original, closed container at room temperature (68°F to 77°F or 20°C to 25°C), away from excessive heat, moisture, and direct light. Do not store this medicine in a bathroom, as humidity can damage it. It is critical to keep all medication, including Clazol, out of the reach and sight of children and pets to prevent accidental ingestion.

To dispose of expired or unused Clazol, the preferred method is to utilize a drug take-back program or mail-back service. If these options are unavailable, and if Clazol is not on the U.S. Food and Drug Administration's flush list for dangerous medications, it can be disposed of in household trash. To do this safely, mix the medicine (without crushing tablets) with an undesirable substance like used coffee grounds or cat litter, place the mixture in a sealed bag or container, and then discard it in the trash. Always remove or scratch out all personal information on the prescription label before discarding the empty packaging.